Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-06-15
2008-09-30
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C546S139000, C548S571000
Reexamination Certificate
active
07429586
ABSTRACT:
Substituted aryloxyalkylamines of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.
REFERENCES:
patent: 3919231 (1975-11-01), Pelosi
patent: 4833149 (1989-05-01), Press
patent: 5182291 (1993-01-01), Gubin et al.
patent: 5217986 (1993-06-01), Pomponi et al.
patent: 5352707 (1994-10-01), Pompni et al.
patent: 5580523 (1996-12-01), Bard
patent: 5580883 (1996-12-01), Goto et al.
patent: 5840746 (1998-11-01), Ducharme
patent: 5869479 (1999-02-01), Kreutner
patent: 5883096 (1999-03-01), Lowe
patent: 5929089 (1999-07-01), Jegham
patent: 6638967 (2003-10-01), Bogenstaetter et al.
patent: 6821980 (2004-11-01), Guerry et al.
patent: 7071191 (2006-07-01), Apodaca
patent: 7241778 (2007-07-01), Apodaca et al.
patent: 19920161 (2000-05-01), None
patent: 0978512 (2000-02-01), None
patent: 982300 (2000-03-01), None
patent: 93/20061 (1993-10-01), None
patent: 95/04052 (1995-02-01), None
patent: 95/14007 (1995-05-01), None
patent: 97/17345 (1997-05-01), None
patent: 99/00186 (1999-01-01), None
patent: 99/42458 (1999-08-01), None
patent: 00/06254 (2000-02-01), None
patent: 00/51720 (2000-09-01), None
patent: 01/32633 (2001-05-01), None
patent: 01/89681 (2001-11-01), None
Albengres, E. et al.; “Systemic Antifungal Agents”; Drug Safety; Feb. 1998; 18(2) :83-97.
Ali, S.M. et al, “Design, Synthesis, and Structure-Activity Relationships of Acetylene-Based Histamine H3 Receptor Antagonists”; J. Med. Chem. ; 1999 42:903-909.
Arrang, J.M. et al; “Auto-inhibition of brain histamine release mediated by a novel class (h3) of histamine receptor” Nature; Apr. 1983: 302:832-837.
Ash, A.S.F. et al; “Receptors Mediating Some Actions of Histamine”; Br. J. Pharmac. Chemother.; 1966 27:427-439.
Back, D.J.; et al; “Inhibition of tolbutamide metabolism by substituted imidazole drugs in vivo:evidence for a structure-activity relationship”; Br. J. Pharmacol.; 1985 85:121-126.
Barnes, J.C. et al; “The selective Histamine H3 Receptor Antagonist Thioperamide Improves Cognition and Enhances Hippocampal Acetylcholine Release in vivo”; Soc. Neurosci. Abstr.; 1993 19:1813.
Black, J.W. et al.; “Definition and Antagonism of Histamine H2-receptors”; Nature. Apr. 1972; 236:385-390.
Caplus English Abstract WO 2001032633 Guerry et al 2001.* Holger Stark et al.: Developments of histamine H3-antagonists, Drugs of the Future, 1996, pp. 507-520, vol. 21, No. 5, XP002084872 Barcelona, ES ISSN: 0377-8282.
Cui, T. et al.: “Fabrication of microreactors for dehydrogenation of cyclohexane to benzene”, Sensors and Actuators B., Elsevier Sequoia S.A., Lausanne, CH, Gd 71, Nr. 3, Dec. 1, 2000, XP004223421.
Ganellin, C.R. et al.: “Synthesis of potent Non-imidazole Histamine H3-Receptor Antagonists” Archiv Der Pharmazie., vol. 331, 1998, pp. 395-404, XP002123596 VCH Verlagsgesellschaft mbH, Weinheim., De ISSN: 0365-6233 cited in the application.
Garbag, M. et al; “S-[2-(4-Imidazolyl)ethyl] Isothiourea, a Highly Specific and Potent Histamine H3 Receptor Agonist”; J. Pharmacol. Exp. Ther.; 1992; 263(1):304-310.
Gilatech, Inc.; “Other News to Note”; Bioworls Today, Mar. 2, 199, p. 3.
Gilatech, Inc.; “Gilatech's first drug candidate begins phase I human clinical trials”; Gilatech Inc. Press Release; Nov. 5, 1998.
Greene Protective Groups in Organic Synthesis (1981).
Ichinose, M. et al; “Histamine H3-receptors modulate nonadrenergic noncholinergic neural bronchoconstriction in guinea-pig in vivo”; P.J. Eur. J. Pharmacol; 1989; 174:49-55.
Imamura, M. et al.; “Unmasking of Activated Histamine H3-Recptors in Myocardial Ischemia: Their Role as Regulators of Exocytotic Norepinephrine Release 1,2”; J. Pharmacol, Exp. ther.; 1994; 271(3):1259-1266.
Kapetanovic, I.M. et al; “Nafimidone, An Imidazole Anticonvulsant, and its Metabolite as Potent Inhibitors of Microsomal Metabolism of Phenytoin and Carbamazepine”; H. J. Drug Metab. Dispos.; 1984 12(5) :560-564.
Korte, A. et al; “Characterization and Tissue Distribution of H3 Histamine Receptors in Guinea Pigs by Na-Methylhistamine”; Biochem. Biophys. Res. Commun.; May 1990; 168(3) :979-986.
Krause, M. et al.; “The Histamine H3 Receptor-A Target for New Drugs”; Leurs, R.; Timmerman, H. (Eds.); Elsevier; 1998;175-196.
Lavrijsen, K. et al; “Induction Potential of Antifungals Containing and Imidazole or Triazole Moiety”; Biochem. Pharmacol.; 1986 35 (11):1867-1878.
Leurs, R. et al; “The medicinal chemistry and therapeutic potentials of ligands of the histamine h3 receptor” Prog. Drug. Res.; 1995; 45:107-165.
Lin, Jiang-Sheng et al. “Involvement of histaminergic neurons in arousaol mechanisms demonstrated with H3-receptor ligands in the cat”; Brain Res.; 1990; 523:325-330.
Linney, Ian D. et al.: “Design, synthesis, and Structure-Activity Relationships of novel Non-imidazole Histamine H3 receptor Antagonists” Journal of Medicinal Chemistry., vol. 43, No. 12, May 20, 2000 (May 20, 2000), pp. 2362-2370, XP001019293 American Chemical Society., US ISSN: 0022-2623 cited in the application.
Lovenberg, T.W. et al; “Cloning and Functional Expression of the Human Histamine H3 Receptor”; Mol. Pharmacol; 1999 55:1101-1107.
Machidori, H. et al; “Zucker obese rats:defect in brain histamine control of feeding”; Brain Res.; 1992; 590:180-186.
McLeod, R.L. et al; “Antimigraine and Sedative Activity of SCH 50971: A Novel Orally-Active Histamine H3 Receptor Agonist”; Soc. Neurosci, Abstr.; 1996; 22:2010.
Meier, G. et al.; “Influence of imidazole replacement in different structural classes of histamine H3-receptor antagonists”; Eur. J. Pharm. Sci.; 2001 13:249-259.
Monti, J.M. et al; “Effects of selective activation or blockade of the histamine h3 receptor on sleep and wakefulness”; Eur. J. Pharmacol.; 1991; 205:283-287.
Morisset, S. et al; “High constitutuive activity of native H3 receptors regulates histamine neurons in brain”; Nature; Dec., 2000; 408:860-864.
Oda, Tamaki et al.; “Molecular Cloning and characterization of a Novel Type of Histamine Receptor Preferentially Expressed in Leukocytes”; J. Biol. Chem.; Nov. 2000; 275(47):36781-36786.
Panula, P. et al.; “Significant Changes in the Human Brain Histaminergic System in Alzheimer's Disease”Soc. Neurosci. Abstr.; 1995; 21:1977.
Phillips, J. G. et al; “The Histamine H3 Receptor-A Target for New Drugs”; Leurs, R.; Timmerman, H. (eds.); Elsevier; 1998; 197-222.
Rouleau, A. et al.; “Bioavailability, Antinociceptive and Antiinflammatory Properties of BP 2-94, a Histamine H3 Receptor Agonist Prodrug”; J. Pharmacol. Exp. Ther.; 1997 281(3) :1085-1094.
Schlicker, E., et al; “The moderate affinity of clozapine at H3 receptors is not shared by its two major metab oiltes and by structurally related and unrelated atypical neuroleptics”; Naunyn-Schmiedeberg's Arch. Pharmacol.; 1996 353:290-294.
Sheets, Joel J., et al.; “Ketoconazole: A Potent Inhibitor of Cytochrome P-450Dependent Drug Metabolism in Rat Liver”, Drug Metab. Dispos.; 1984 12(5) :603-606.
Starks, H. et al.: “Developments of histamine H3- antagonists” Drugs of the Future, vol. 21, No. 5, 1996, pp. 507-520, XP002084872 Barcelona, ES ISSN: 0377-8282 cited in the application.
Starke, H. et al.: “General Construction Patterb of Histamine H3-Receptor Antagonists: Change of a paradigm” Bioorganic & Medicinal Chemistry Letters, No. 8, 1998, pp. 2011-2016, XP004137177 Oxford, GB ISSN: 0960-894X.
Tozer, M.J., et al.: “Histamine H3 receptor antagonists” Exp. Opinion. Ther. Patents; 2000 10:1045-1055.
Walczynski, K. et al, “Non-Imidazole Histamine H3 Ligands, Part 2: New 2-Substituted Benzothiazoles as Histamine H3 Antagonists”; Arch. Pharm. Pharm. Med. Chem
Apodaca Richard
Carruthers Nicholas I.
Dvorak Curt A.
Rudolph Dale A.
Shah Chandravadan R.
Ortho-McNeil Pharmaceuticlas, Inc.
Saeed Kamal A.
LandOfFree
Non-imidazole aryloxyalkylamines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-imidazole aryloxyalkylamines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-imidazole aryloxyalkylamines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3978339